Syngene stock rating improves to Sell as fundamentals remain weak

Published on 11/13/2026 at 02:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Syngene stock faces a cautious reset after MarketsMojo moved its rating to Sell. Technical signals improved, but profitability remains weak.

Rating Turns Less Bearish

MarketsMojo moved Syngene's rating from Strong Sell to Sell as technical signals shifted toward a sideways trend.
Profitability, returns and valuation remain pressure points after the second quarter recovery.
Syngene's next results and operating progress will be central to any broader reassessment.

Syngene, INE398R01022, Illustration mit AI erstellt.

MarketsMojo moved its rating on Syngene International from Strong Sell to Sell on November 9, citing improved technical signals but continuing concerns over profitability, returns and valuation. The assessment, published on November 10, described the share trend as sideways rather than decisively bullish.

The analysis said Syngene's second-quarter fiscal 2027 performance showed financial pressure despite a sequential recovery. Profit before tax excluding other income was reported at INR 25.70 crore, while profit after tax was INR 36.79 crore. MarketsMojo also highlighted a five-year annualized contraction in operating profit and returns on capital employed of 7.32 percent for the first half.

Technical Signals Improve

MarketsMojo said weekly MACD and Bollinger Band readings had improved, while monthly indicators remained weaker. The mixed picture supported a less negative rating without signalling a full turnaround. The analysis also cited a price-to-book ratio of 3.6 and continuing underperformance over longer periods.

Syngene stock last traded at 447.80 Indian rupees on the National Stock Exchange at 3:30 p.m. IST on Thursday, November 12. The quote is the latest available market reading and is shown without a comparison to a euro trading venue.

The company published second-quarter results for the period ended September 30, 2026, after a sequential revenue recovery and improved operating margins. Its first manufacturing agreement for the Bayview biologics facility in the United States remains a key commercial development, while lower Zoetis-related revenue and foreign-exchange effects weighed on the year-on-year comparison.

Research And Manufacturing Platform

According to Syngene's investor information, the Bengaluru-based company provides integrated research, development and manufacturing services from early discovery through commercial supply. Its customers include pharmaceutical, nutrition, animal health, consumer goods and specialty chemical companies, with operations serving clients in India, the United States and other international markets. Syngene is a broad contract research and manufacturing organization within the Biocon group, combining discovery, development and manufacturing capabilities rather than focusing on a single service line.